Followers | 2540 |
Posts | 250759 |
Boards Moderated | 35 |
Alias Born | 05/06/2014 |
Wednesday, April 13, 2016 12:03:41 AM
Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that their Bangkok office that will be utilized to typify the live cells utilized for PharmaCyte’s pancreatic malignancy treatment has come under the scanner of Food and Drug Administration of Thailand (Thai FDA). The company is focused on developing medicines for tumor and diabetes utilizing its mark live-cell embodiment innovation Cell-in-a-Box.
The Thai FDA confirmed in its report that the office has been build in accordance to a permitted floor plan and is presently considered suitable for the assembling of pharmaceutical items.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, remarked that they were happy that Austrianova has gotten a positive sentiment from the Thai FDA for Austrianova’s live-cell office.
Positive News
This is an imperative turning point in the improvement of PharmaCyte’s treatment for pancreatic malignancy and a pre-essential for our up and coming pancreatic disease clinical trial. The primary part of the Thai FDA is to secure customer’s wellbeing, particularly, to guarantee wellbeing, quality and viability of wellbeing items inside of its domain.
These items include food, drugs, psychotropic substances, opiates, restorative gadgets, unstable substances, beauty care products and risky substances. It is a flat out necessity that the development and operation of Austrianova’s live-cell epitome office be as per both Thai national enactment and also global understandings.
PharmaCyte’s item for pancreatic growth will be fabricated in Austrianova’s office in Bangkok. It comprises of live human cells that have been hereditarily designed to change over the anticancer prodrug ifosfamide into its malignancy murdering structure and afterward exemplified utilizing the Cell-as a part of a-Box epitome innovation.
Pancreatic Growth Cells Destruction
In PharmaCyte’s upcoming clinical trial, these epitomized live cells will be utilized with low measurements of ifosfamide (33% the ordinary dosage) as a “combination treatment” with the present standard of tend to cutting edge pancreatic growth when a patient no more advantages from first line treatment.
PharmaCyte’s treatment will be contrasted and the blend of the anticancer medication capecitabine in addition to radiation in patients with privately progressed, non-metastatic, inoperable pancreatic disease whose tumors are steady or advancing after 4-6 cycles of treatment with either the mix of Abraxane in addition to gemcitabine or the four-drug mix known as FOLFIRINOX.
http://mmjreporter.com/pharmacyte-biotech-inc-otcmktspmcb-bangkok-office-comes-under-thai-fda-scanner-1251/
Recent PMCB News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/13/2024 08:37:40 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/29/2024 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM